MoonLake Immunotherapeutics (NASDAQ:MLTX) Earns Buy Rating from HC Wainwright

MoonLake Immunotherapeutics (NASDAQ:MLTX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $32.00 price target on the stock, up from their prior price target of $26.00. HC Wainwright’s target price suggests a potential upside of 73.07% from the stock’s previous close.

Several other brokerages have also recently weighed in on MLTX. Guggenheim reduced their price target on MoonLake Immunotherapeutics from $80.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 30th. Stifel Nicolaus lowered shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $13.00 target price for the company. in a report on Monday, September 29th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $7.00 target price on shares of MoonLake Immunotherapeutics in a research note on Wednesday, October 1st. Citigroup lowered shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research report on Wednesday, October 29th. Finally, Needham & Company LLC decreased their price objective on shares of MoonLake Immunotherapeutics from $66.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 30th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $25.54.

MoonLake Immunotherapeutics Trading Up 28.9%

NASDAQ MLTX opened at $18.49 on Friday. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75. The company has a debt-to-equity ratio of 0.25, a current ratio of 8.50 and a quick ratio of 8.50. The company has a market capitalization of $1.19 billion, a PE ratio of -5.57 and a beta of 1.21. The company has a fifty day moving average of $13.18 and a 200 day moving average of $31.46.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same quarter last year, the firm posted ($0.56) earnings per share. Research analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other news, CEO Da Silva Jorge Santos sold 70,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total value of $1,014,300.00. Following the sale, the chief executive officer owned 2,878,577 shares in the company, valued at $41,710,580.73. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Kristian Reich sold 72,908 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total transaction of $1,052,062.44. The SEC filing for this sale provides additional information. In the last three months, insiders sold 402,908 shares of company stock valued at $5,987,162. 12.02% of the stock is owned by insiders.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Institutional investors have recently bought and sold shares of the company. Schonfeld Strategic Advisors LLC purchased a new stake in MoonLake Immunotherapeutics during the 3rd quarter worth approximately $6,922,000. Two Sigma Investments LP purchased a new stake in shares of MoonLake Immunotherapeutics during the third quarter worth approximately $3,257,000. Vestal Point Capital LP increased its position in shares of MoonLake Immunotherapeutics by 175.0% during the second quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock worth $25,960,000 after purchasing an additional 350,000 shares in the last quarter. Balyasny Asset Management L.P. raised its stake in MoonLake Immunotherapeutics by 436.8% in the 2nd quarter. Balyasny Asset Management L.P. now owns 423,170 shares of the company’s stock valued at $19,974,000 after purchasing an additional 344,335 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in MoonLake Immunotherapeutics by 3,343.2% in the 1st quarter. Millennium Management LLC now owns 344,320 shares of the company’s stock valued at $13,453,000 after purchasing an additional 334,320 shares in the last quarter. 93.85% of the stock is currently owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics News Roundup

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: FDA feedback may allow a skin drug filing for SLK without new clinical trials, reducing regulatory risk and supporting a faster BLA path. MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars
• Positive Sentiment: HC Wainwright reaffirmed a Buy and raised its price target to $32, signaling stronger analyst conviction and giving investors a higher upside benchmark. Benzinga: HC Wainwright rating/price target
• Positive Sentiment: Needham maintained a Buy rating and $20 target, citing regulatory de‑risking on HS and 2026 inflammatory disease catalysts as supporting the investment case. MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating
• Positive Sentiment: Retail momentum and speculation about potential M&A conversations amplified the rally, attracting heavy trading volume and short‑term buying interest. MLTX stock extends rally as FDA feedback spurs bullish brokerage action – retail speculates on potential M&A conversations
• Neutral Sentiment: Analysts and commentators view the FDA Type B meeting as momentum ahead of a planned BLA submission; this is positive if regulators agree but not a guarantee of approval. MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission
• Neutral Sentiment: Explanatory pieces trace the pre‑market surge and investor interest — useful for context but not new catalyst information. Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Up 34.28%
• Negative Sentiment: Fundamentals remain loss‑making (recent EPS misses and negative forecasted EPS), and regulatory outcomes or labeling negotiations could still require additional data or post‑market commitments. Investors should weigh binary regulatory risk and past volatility. MarketBeat MLTX profile (financials & recent results)

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.